Document Detail


Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
MedLine Citation:
PMID:  14606259     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Drug tolerability strongly influences patients' persistence with treatment. In this study, patterns of medication persistence with cyclooxygenase 2 (COX-2)-specific inhibitors and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) were compared in a managed care setting. Pharmacy, enrollment, and medical claims data from 19 health plans were used to match subjects newly treated with celecoxib, rofecoxib, ibuprofen, naproxen, or diclofenac between July 1, 1999 and June 30, 2000. By using multiple regression analysis, users of COX-2-specific inhibitors were found to be 56.8% less likely to discontinue medication use and 60.3% less likely to switch treatment than were users of nonspecific NSAIDs (P < .001). Celecoxib users were 4.6% less likely to discontinue treatment than were rofecoxib users (P < .001). The greater persistence observed among users of COX-2 inhibitors might reflect improved treatment efficacy and patient satisfaction.
Authors:
Carolyn Harley; Samuel Wagner
Related Documents :
17439699 - Hyperbaric oxygen and carbon monoxide poisoning: a critical review.
9597979 - Medical treatment of essential tremor and parkinson's disease.
3279829 - The right to refuse treatment with antipsychotic medications: retrospect and prospect.
12906229 - Odds of moderate or severe gastric ulceration in racehorses receiving antiulcer medicat...
10749449 - Fibrous osteodystrophy in dromedary camels (camelus dromedarius).
20012329 - Assessment of severity of acute pancreatitis according to new prognostic factors and ct...
18771039 - The federal government and academic texts as barriers to informed consent.
22426889 - Clinical evidence of particle beam therapy (proton).
21359579 - Tuberculosis among participants in an academic global health medical exchange program.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Managed care interface     Volume:  16     ISSN:  1096-5645     ISO Abbreviation:  Manag Care Interface     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-11-10     Completed Date:  2004-01-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9715194     Medline TA:  Manag Care Interface     Country:  United States    
Other Details:
Languages:  eng     Pagination:  38-45     Citation Subset:  H    
Affiliation:
Research and Data Solutions at Ingenix, Inc., Eden Prairie, Minnesota, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / economics,  therapeutic use*
Arthritis / classification,  drug therapy*,  economics
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / economics,  therapeutic use*
Diclofenac / therapeutic use
Drug Utilization Review / statistics & numerical data*
Female
Health Care Costs / classification,  statistics & numerical data
Humans
Ibuprofen / therapeutic use
Insurance Claim Review
Isoenzymes
Lactones / therapeutic use
Male
Managed Care Programs / economics*,  organization & administration
Membrane Proteins
Middle Aged
Naproxen / therapeutic use
Patient Compliance / statistics & numerical data*
Proportional Hazards Models
Prostaglandin-Endoperoxide Synthases
Pyrazoles
Regression Analysis
Sulfonamides / therapeutic use
Sulfones
United States
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Cyclooxygenase Inhibitors; 0/Isoenzymes; 0/Lactones; 0/Membrane Proteins; 0/Pyrazoles; 0/Sulfonamides; 0/Sulfones; 0/rofecoxib; 15307-86-5/Diclofenac; 15687-27-1/Ibuprofen; 169590-42-5/celecoxib; 22204-53-1/Naproxen; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/PTGS2 protein, human; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The implementation of Medicaid managed care for pregnant women in Ohio: a case study.
Next Document:  Inhibition of herpes simplex virus type 1 by aqueous extracts from leaves of Helichrysum litoreum Gu...